Naurex

iBIO Institute announces iCON Awards honorees

Tuesday, August 22, 2017

The iBIO Institute announced the four honorees of the eleventh annual iCON Awards—a prestigious honor for life sciences educators, researchers and civic visionaries. The iCON Awards celebrate the accomplishments of outstanding innovators and leaders whose work provides the basis for biotechnology developments worldwide.

[Read More]

Allergan to acquire Naurex

Monday, July 27, 2015

Allergan, a global pharmaceutical company based in Dublin, has agreed to acquire Naurex, an Evanston, Ill.-based clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, in an all-cash transaction. Allergan will acquire Naurex for a $560 million, up-front payment, $460 million of which is payable upon the closing of the acquisition, as well as potential R&D success-based and sales-threshold milestone payments. 

[Read More]

Report: Midwest healthcare companies raise $1.8B in 2014

Wednesday, January 21, 2015

Midwest healthcare companies attracted $1.8 billion in new investments across 243 companies in 2014, according to the BioEnterprise Midwest Healthcare Growth Capital Report. The totals are the highest recorded in both dollars and number of companies funded since BioEnterprise began compiling the report in 2005, surpassing the banner 2007 by 46% and 2013 by 135%. BioEnterprise is a business formation, recruitment, and acceleration initiative designed to grow healthcare companies and commercialize bioscience technologies based in Cleveland, Ohio.

[Read More]

Naurex completes $18 Million Series A

Wednesday, May 11, 2011

Naurex, a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, has completed an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners. 

[Read More]